RE:RE:RE:Biotech777Hi jdstox.
Your point about the power of perception is precisely what I've been trying to emphasize in previous posts. RVX has a number of important markets and stakeholders to address and manage their perceptions of the successes. The June 2013 release of trial results was a complete failure in the management of perceptions and we all felt the rather devasting results. Scientists, doctors, and researchers are human and are strongly influeneced by perception. For example, consider the power of drug reps on medical doctors. So much of the influence is about the relationship between the doc and rep and the rep contolling the doc's beliefs, understanding, trust and confidence...
the rep controlling the agenda. Psychologists, psychological economists and market researchers have long realized the limited and misleading beliefs based on "the rational man" model. Likewise, most shareholders are operating at least as much on an emotional level as a rational 'level.
All I'm saying is that RVX doesn't see this gapeing shortfall. However, if the key is the "deal" it may not matter. And, given the challenges they face I'm sure perception management is not on their radar. And yet, had June 2013 been managed effectively, they may be playing a far more positive chess game than the current situation.
Anyway, it's water under the bridge and I'll leave it alone. They are a compent team and will manage forward. Afterall, they have for 14 years.
Cheers
Toinv
| "as an additive to statin therapy. I think the market views it as such. That means less of a market value for RVX-208 because the statin costs money to administer as well, and there has to be return for that. There is also the perception, probably wrong but existent nevertheless, that RVX-208 doesn't work without statins, and a select few statins, at that. | |